{"id":10422,"date":"2024-06-03T02:34:29","date_gmt":"2024-06-03T02:34:29","guid":{"rendered":"https:\/\/economicherald.net\/?p=10422"},"modified":"2024-06-03T02:34:29","modified_gmt":"2024-06-03T02:34:29","slug":"asx-health-stocks-inoviq-pops-45pc-after-revealing-breakthrough-exosome-therapy-to-kill-breast-cancer","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=10422","title":{"rendered":"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer"},"content":{"rendered":"

INOVIQ\u2019s exosomes therapy to target breast cancer cells<\/p>\n

INOVIQ (ASX:IIQ)<\/a> said it has created specialised exosomes (EEVs) designed to target and destroy breast cancer cells in a lab setting.<\/p>\n

Using a special protein called a chimeric antigen receptor (CAR)<\/em>, the exosomes were engineered by immune cells to specifically attack breast cancer cells.<\/p>\n

These modified exosomes were then isolated and concentrated using INOVIQ\u2019s proprietary EXO-ACE<\/strong> technology, which recovered more than 80% of exosomes with over 95% purity.<\/p>\n

In tests, 75% of breast cancer cells treated with these exosomes experienced cell death within 72 hours.<\/p>\n

Encouraged by these promising results, INOVIQ said it plans to further develop its exosome therapeutics program, initially focusing on using immune-cell derived exosomes to treat metastatic breast and ovarian cancers.<\/p>\n

Additionally, exosomes can be engineered and loaded with drug cargo, such as RNA therapeutics, to target and deliver effective treatments for neurological diseases across the blood-brain barrier.<\/p>\n

CEO Leearne Hinch<\/strong> said INOVIQ has established core capabilities in-house to engineer, load and produce exosomes for therapeutic applications.<\/p>\n

\u201cThese data highlight the potential of immune-cell derived exosomes as an effective cancer therapy and the potential for RNA drug-loaded exosome therapeutics,\u201d Hinch said.<\/p>\n

The company is now is now moving forward with this program, as it\u00a0aims to advance towards key preclinical in vitro and in vivo milestones for cancer starting in CY24.<\/p>\n

\u201cPreclinical in vivo data are expected to support discussions with pharmaceutical companies for potential partnered exosome therapeutic opportunities,\u201d Hinch added.<\/p>\n

INOVIQ\u2019s share price was up +45% this morning.<\/p>\n

\u00a0<\/p>\n

Telix seeks FDA approval for kidney cancer imaging agent<\/h2>\n

Telix Pharmaceuticals (ASX:TLX)<\/a><\/strong> has completed the submission of a Biologics License Application (BLA)<\/em> to the US FDA for its investigational radiodiagnostic PET agent, TLX250-CDx<\/strong>.<\/p>\n

This application seeks to classify kidney masses as clear cell renal cell carcinoma (ccRCC)<\/strong>, which is the predominant and aggressive form of kidney cancer.<\/p>\n

The submission was based on the successful global Phase III ZIRCON<\/em> study, which demonstrated high sensitivity and specificity for ccRCC detection.<\/p>\n

Telix has also requested a Priority Review<\/em> to expedite the FDA\u2019s evaluation process. If approved, TLX250-CDx would be the first targeted radiopharmaceutical imaging agent specifically for kidney cancer commercially available in the US.<\/p>\n

Telix has launched programs in different regions like the US, Europe, and Australia to give patients continued access to TLX250-CDx outside of clinical trials. These programs are for patients who don\u2019t have other suitable treatment options available.<\/p>\n

James Stonecypher, Telix\u2019s chief development officer<\/em>, says completing the BLA submission for TLX250-CDx brings its breakthrough kidney cancer imaging agent closer to being available in the market as a non-invasive diagnostic tool for patients.<\/p>\n

\u201cWe believe TLX250-CDx is a natural follow-on product to Illuccix as it is targeted at the same clinical stakeholders, the urologist and urologic oncologist, and leverages the proven commercial and distribution infrastructure developed through the launch of Illuccix,\u201d he said.<\/p>\n

Telix\u2019s share price was flat this morning.<\/p>\n

\u00a0<\/p>\n

Share prices today:<\/h2>\n

\u00a0<\/p>\n\n

\ufeff<\/span><\/span>\u00a0
\n<\/span><\/p>\n

The post ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

INOVIQ\u2019s exosomes therapy to target breast cancer cells INOVIQ (ASX:IIQ) said it has created specialised exosomes (EEVs) designed to target and destroy breast cancer cells [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":10423,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-10422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"\nASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=10422\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"INOVIQ\u2019s exosomes therapy to target breast cancer cells INOVIQ (ASX:IIQ) said it has created specialised exosomes (EEVs) designed to target and destroy breast cancer cells [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=10422\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-03T02:34:29+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer\",\"datePublished\":\"2024-06-03T02:34:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422\"},\"wordCount\":528,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=10422\",\"name\":\"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg\",\"datePublished\":\"2024-06-03T02:34:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=10422\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10422#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=10422","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer - Economic Herald","og_description":"INOVIQ\u2019s exosomes therapy to target breast cancer cells INOVIQ (ASX:IIQ) said it has created specialised exosomes (EEVs) designed to target and destroy breast cancer cells [more...]","og_url":"https:\/\/economicherald.net\/?p=10422","og_site_name":"Economic Herald","article_published_time":"2024-06-03T02:34:29+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=10422#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=10422"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer","datePublished":"2024-06-03T02:34:29+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=10422"},"wordCount":528,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=10422#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=10422","url":"https:\/\/economicherald.net\/?p=10422","name":"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=10422#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=10422#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg","datePublished":"2024-06-03T02:34:29+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=10422#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=10422"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=10422#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/INOVIQs-exosomes-therapy-to-target-breast-cancer-cells.-Picture-Getty-uKt84S.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=10422#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/10422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10422"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/10422\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/10423"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}